September 23, 2026: NCHR’s Diana Zuckerman testifies at FDA panel meeting on Galleri multi-cancer screening test, stating that the test fails to accurate predict early cancers. The test misses more early cancers than a coin toss, and those false negatives can lead to patients delaying medical visits when symptoms appear. Those delays can be deadly. Though the test is less likely to tell people they have cancer when they don’t, those who are misinformed will undergo many weeks of anxiety as well as additional, often invasive tests. Most important, there is no evidence that the test saves lives or improves quality of life, since most cancers detected are late stage.
Read More »On Medical Treatments & Products
NCHR Written Comment on FDA’s Review of the Galleri Multi-Cancer Early Detection Test
September 8, 2026: In response to a request for public comments, NCHR urged the FDA not to approve Galleri multi-cancer screening blood test until it is proven to help patients live longer or improve their quality of life. Its accuracy must be improved to show its benefits outweigh the physical, emotional, and financial burdens of inaccurate results and follow-up testing. NCHR also emphasized Galleri’s limited sensitivity, particularly for early-stage cancers, and warned that it should not replace recommended cancer screenings.
Read More »Testimony of Dr. Diana Zuckerman at the FDA Oncology Drugs Advisory Committee on TRUQAP
FDA Oncology Advisory Committee on TRUQAP, April 30, 2026: NCHR president Dr. Diana Zuckerman expressed her concerns about the serious risks and uncertain benefits of TRUQAP given that there is no evidence that it improves overall survival
Read More »Testimony of Dr. Diana Zuckerman at the FDA Oncology Drugs Advisory Committee on Breast Cancer
FDA Oncology Advisory Committee, April 30, 2026: NCHR president Dr. Diana Zuckerman expressed her concerns about uncertain evidence in the SERENA-6 trial of camizestrant in patients with ER+HER2 advanced breast cancer in combination with a CDK4/6 inhibitor plus aromatase inhibitor upon detection of an ESRI biomarker.
Read More »NCHR Written Comment to AHRQ on Improving the Management of Menopausal Symptoms in Perimenopausal and Early Postmenopausal Women
May 13, 2026, NCHR submitted comments in response to AHRQ’s request for feedback on its research protocol that will inform the NIH Pathways to Prevention Workshop on Improving the Management of Menopausal Symptoms. NCHR urged AHRQ to include all relevant studies rather than exclude foundational evidence through publication date cutoffs. We are especially concerned at the exclusion of long-term Women’s Health Initiative (WHI) findings, and to provide unbiased, easy-to-understand information about the risks and benefits of different menopause treatments.
Read More »